SciSparc (SPRC) Debt Ratio (2018 - 2025)
SciSparc (SPRC) posted Debt Ratio of 0.05 for Q4 2025, up 31.88% sequentially from 0.04 in Q2 2025, and down 88.56% YoY from 0.41 in Q4 2024.
SciSparc (SPRC) Debt Ratio (2018 - 2025) Analysis & Trends
SciSparc has reported Debt Ratio for 5 years, with the latest figure at 0.05 in Q4 2025.
- Quarterly Debt Ratio fell 88.56% year-over-year to 0.05 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.05 (down 88.56% YoY) and the FY2025 annual result came in at 0.05, down 88.56% from the prior year.
- Debt Ratio improved to 0.05 in Q4 2025 per SPRC's latest filing, from 0.04 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.41 in Q4 2024 and troughed at 0.04 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.26 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.47 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.03 |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - | 0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.05 |
| Jun 30, 2025 | 0.04 |
| Dec 31, 2024 | 0.41 |
| Dec 31, 2020 | 0.07 |
| Jun 30, 2020 | 0.04 |
| Jun 30, 2019 | 0.48 |
| Dec 31, 2018 | 0.17 |